Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treatment targeted to cell surface epitopes.

U Mrowietz1

  • 1Department of Dermatology, University of Kiel, Germany. umrowietz@dermatology.uni-kiel.de

Clinical and Experimental Dermatology
|December 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Depression, a major comorbidity of psoriatic disease, is caused by metabolic inflammation.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Same author

[Systemic treatment of moderate/severe hidradenitis suppurativa].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2021
Same author

ActiPso: definition of activity types for psoriatic disease: A novel marker for an advanced disease classification.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Same author

Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study.

The British journal of dermatology·2021
Same journal

Real-World Outcomes of Stapokibart-Based Combination Therapy for Bullous Pemphigoid: A Single-Center Retrospective Cohort.

Clinical and experimental dermatology·2026
Same journal

Male genital fixed drug eruption: a systematic review.

Clinical and experimental dermatology·2026
Same journal

Treatment Trajectories and Dose Optimization of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A Real-World Landmark Analysis.

Clinical and experimental dermatology·2026
Same journal

Cutaneous features of SDR9C7 variants in eight subjects with autosomal recessive nonsyndromic epidermal differentiation disorders.

Clinical and experimental dermatology·2026
Same journal

A Review of Male Genital Psoriasis.

Clinical and experimental dermatology·2026
Same journal

Outcome measure instruments for the assessment and treatment of androgenetic alopecia: A scoping review.

Clinical and experimental dermatology·2026
See all related articles

Receptor-targeted therapies show promise for inflammatory skin diseases like psoriasis by modulating immune cell surface epitopes. However, clinical efficacy and safety vary, necessitating further research into optimal treatment strategies.

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Immune cells express surface epitopes, including receptors and adhesion molecules, which are modulated during activation.
  • These epitopes are crucial for identifying immune cell types and their activity status in inflammatory skin diseases.
  • Targeting cellular surface epitopes with monoclonal antibodies and fusion proteins offers a therapeutic principle for modulating cellular function.

Purpose of the Study:

  • To review the development of receptor-targeted treatments for skin disorders, with a primary focus on psoriasis.
  • To discuss clinical and experimental data regarding the efficacy, safety, and tolerability of various receptor-targeted compounds.

Main Methods:

  • Literature review of clinical trials and experimental studies on receptor-targeted therapies for skin disorders.

Related Experiment Videos

  • Analysis of data on the clinical efficacy, safety, and tolerability of different therapeutic compounds.
  • Discussion of the modulation of immune cell surface epitopes in the context of inflammatory skin diseases.

    • Main Results:

    • Receptor-targeted therapy has been developed and extensively tested for psoriasis.
    • The effectiveness of these therapeutic strategies is not uniform, with varying clinical outcomes.
    • Data on clinical efficacy, safety, and tolerability are available for several compounds.

    Conclusions:

    • Receptor-targeted therapies represent a significant approach in treating inflammatory skin disorders, particularly psoriasis.
    • The efficacy and safety profiles of current receptor-targeted treatments vary considerably.
    • Further investigation is needed to optimize these therapies for improved clinical outcomes.